Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Stefanie HammerUrs B HagemannSabine Zitzmann-KolbeAasmund LarsenChristine EllingsenSolene GeraudieDerek GrantBaard IndrevollRoger SmeetsOliver von AhsenAlexander KristianPascale LejeuneHartwig HennekesJenny KarlssonRoger M BjerkeOlav B RyanAlan S CuthbertsonDominik MumbergPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The strong preclinical antitumor activity of PSMA-TTC supports its clinical evaluation, and a phase I trial is ongoing in mCRPC patients (NCT03724747).
Keyphrases
- pet ct
- prostate cancer
- pet imaging
- clinical evaluation
- cancer therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- cell therapy
- radical prostatectomy
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- open label